Data set from Nano G, Muzzarelli L, Malacrida G, Righini PC, Marrocco-Trischitta MM, Mazzaccaro D. Endovascular repair of thoracic and thoraco-abdominal aortic lesions. Ann Ital Chir. 2019;90:191-200. PMID: 31354152.

Data set from Nano G, Muzzarelli L, Malacrida G, Righini PC, Marrocco-Trischitta MM, Mazzaccaro D. Endovascular repair of thoracic and thoraco-abdominal aortic lesions. Ann Ital Chir. 2019;90:191-200. PMID: 31354152. This is the abstract: <strong>Background: </strong> We report our "real-world" experience of endovascular repair of thoracic/thoraco-abdominal aortic lesions in patients treated from May 2002 to May 2017. <strong>Methods: </strong> Data of all consecutive treated patients were retrospectively collected in a database and analyzed. Patients were divided into 4 groups: atherosclerotic thoracic/thoraco-abdominal aneurysms (TAA/TAAA) and floating thrombus (group A); acute complicated type B dissection (TBD), penetrating aortic ulcers (PAU) and intra-mural hematomas (IMH) in group B; chronic TBD evolving in TAA (group C); traumatic injuries (group D). Mortality, reinterventions and occurrence of neurological complications, both at 30 days and in the long term, were analyzed as primary outcomes for each group. <strong>Results: </strong> Ninety-four patients were treated complessively, most for a TAA (55.3%). Thirty-days deaths and neurological complications were observed in group A only (5 cases each, 5.3%). A reintervention was necessary in 6 patients (6.4%) of group A. At 5 years, in group A survival was 62.8%±6.3% and freedom from neurological complication was 88.3%±4.2%. Neither deaths nor neurological complications were recorded in the other groups. No late aortic ruptures were recorded. Freedom from reintervention in group A was 54.7%±7.6% at 5 years and a reintervention was needed in all patients of group D. Overall, the main cause for reintervention was a type I endoleak. <strong>Conclusions: </strong> The endovascular repair of thoracic/thoraco-abdominal aortic lesions had acceptable mortality and neurological complication rates, both at 30 days and in the long term. Reinterventions in the long term occurred more frequently after TAA/TAAA and traumatic injuries, and were mainly required for a type I endoleak.本数据集源自Nano G、Muzzarelli L、Malacrida G、Righini PC、Marrocco-Trischitta MM、Mazzaccaro D的研究。原文发表于《意大利外科学年鉴》（Ann Ital Chir）2019年；90卷：191-200页，PMID: 31354152。以下为该研究的摘要： **背景：** 本研究报告了2002年5月至2017年5月期间接受胸/胸腹主动脉病变血管腔内修复术患者的真实世界诊疗经验。 **方法：** 本研究对连续收治的所有接受治疗患者的资料进行回顾性收集并纳入数据库分析。将患者分为4组：动脉粥样硬化性胸/胸腹主动脉瘤（TAA/TAAA）伴漂浮血栓组（A组）；复杂性急性B型主动脉夹层（TBD）、主动脉穿透性溃疡（PAU）及主动脉壁内血肿（IMH）组（B组）；慢性B型主动脉夹层进展为胸主动脉瘤组（C组）；创伤性主动脉损伤组（D组）。以各组的30天及远期死亡率、再干预率与神经系统并发症发生率作为主要研究终点进行分析。 **结果：** 本研究共计纳入94例接受治疗的患者，其中多数为胸主动脉瘤患者（55.3%）。仅A组出现30天死亡及神经系统并发症（各5例，占比5.3%）。A组有6例患者（6.4%）需接受再干预。术后5年时，A组生存率为62.8%±6.3%，无神经系统并发症比例为88.3%±4.2%。其余各组均未记录到死亡及神经系统并发症，亦未出现远期主动脉破裂。A组术后5年无再干预比例为54.7%±7.6%，而D组所有患者均需接受再干预。总体而言，再干预的主要原因为I型内漏（type I endoleak）。 **结论：** 胸/胸腹主动脉病变的血管腔内修复术在30天及远期均具有可接受的死亡率与神经系统并发症发生率。远期再干预更多见于胸/胸腹主动脉瘤及创伤性主动脉损伤患者，其主要诱因均为I型内漏（type I endoleak）。